Adalank

Adalank is a synthetic peptide analogue of selank, with targeted chemical alteration.

 

 

SKU: 198803 Kategori:
Pataje lanmou w

Adalank is a synthetic peptide analogue of selank, with targeted chemical alteration.

The peptide is designed as a derive nan la nootropic drug Selank, with the addition of an acetylated N-terminal function that enhances its adamantane-like sterically-constraining structure.

This modification acts as a powerful synergistic potentiator of the anxiolytic – nootropic compound Selank.

It circumvents Selank’s poor baryè san-sèvo (BBB) pénétration, thereby increasing the central nervous system activity of Adalank significantly.

The addition of an acetyl group eliminates the positive charge of the N-terminal free amino group and decreases the net charge of the peptide.

This physicochemical adjustment optimizes the pwen izoelektrik and surface properties of Adalank, reducing non-specific electrostatic interactions.

Kòm yon rezilta, the drug molecule crosses the blood–brain barrier more easily and reaches the central nervous system.

Anplis de sa, asetilasyon protects Adalank from exopeptidase degradation and significantly increases its in vivo half-life.

This provides the advantage of prolonged therapeutic blood levels and reduces frequent dosing.

The inclusion of adamantane creates a stable “conformation core” in the Adalank peptide.

This imparts a fixed spatial orientation to the initially flexible linear peptide, promoting the stereochemical conformation necessary for biological activity even in its unbound state.

This greatly improves Adalank’s ability to cross the blood-brain barrier.

Anplis de sa, Adalank exhibits certain immunomodulatory effects.

Sekans

ac-thr-lys-pro-arg-pro-gly-pro-Adamantane-nh2

Nimewo CAS

/

Fòmil molekilè

C46H75N13O10

Pwa molekilè

970.19

Research Of Adalank:

1.Mekanis aksyon

Efikasite-ki gen bon konprann, Adalank’s rigid structure more closely corresponds to the allosteric modulation site of the GABA_A receptor alpha subunit, imparting stronger anksyolitik efè.

Anplis, the adamantane moiety enables hydrophobic interactions in the Reseptè NMDA channel area to moderate calcium influx and protect against excitotoxic injury.

This property has the potential for neropwoteksyon in models of ischemic brain injury and post-traumatic stress disorder (PTSD).

2.Anxiolytic Effects

As an optimized derivative of Selank, Adalank maintains a high-affinity interaction with the benzodiazepine site on the GABA_A receptor α-subunit.

Sepandan, the N-terminal acetylation and adamantane scaffold shift the binding mode from “flexible induced fit” to “rigid precise docking”.

This enhances GABAergic inhibitory neurotransmission, promoting chloride influx and rapid reduction of activity in hyperactive amygdala-prefrontal cortex neural circuits.

In contrast to benzodiazepines, Adalank shows high receptor subtype selectivity, enabling sustained anxiolytic effects without the sedation, muscle relaxation, or addiction potential associated with traditional drugs.

Its therapeutic index se 3 pou 5 times wider, supporting long-term management of generalized anxiety disorder and situational anxiety disorders.

3.Cognitive Enhancement and Memory Improvement

Adalank effectively inhibits the activation of the NF-κB inflammatory pathway and increases BDNF mRNA expression by 50%-80% in the hippocampus.

This leads to activation of downstream Akt/CREB chemen siyal yo, facilitating LTP induction and maintenance.

It significantly improves memory retention in passive avoidance tests, enhances spatial learning in the Morris water maze, and counteracts scopolamine-induced cholinergic damage.

Preclinical data indicate that Adalank reduces working memory errors by 40%-60% and mitigates natural memory decline in aged animals, suggesting applicability in learning disorders, mild cognitive impairment, and age-related memory decline.

4.Efè neropwotektif

The adamantane structure in Adalank mimics the action of memantine, acting as a non-competitive Reseptè NMDA antagonist that causes voltage-dependent blockade of open channels and physiological regulation of calcium influx.

It reduces pathological Ca²⁺ influx by 60–70% without impairing physiological synaptic Ca²⁺ signaling, achieving a selective neuroprotective profile without disrupting normal function.

Kidonk, preclinical studies highlight Adalank’s significant translational potential for early intervention in acute stroke, spinal cord injury, epi maladi neurodegenerative.

COA

HPLC

MS

(1) Nou vle, C. R.; Blan, C. M. Ajan sedatif-ipnotik ki afekte reseptè asid Gamma-Aminobutyric: Konsantre sou Flunitrazepam, Gamma-Hydroxybutyric Asid, Phenibut, ak Selank. J Clin Pharmacol 2021, 61 Suppl 2, S114-S128. DOI: 10.1002/jcph.1922 From NLM M

(2) Pòv bagay, A.; Kolomin, T.; Andreeva, L.; Bondarenko, E.; Myasoedov, N.; Slominsky, P.; Shadrina, M. Peptide Selank amelyore efè dyazepam nan diminye enkyetid nan kondisyon estrès kwonik enprevizib nan rat.. Konpòtman Neurol 2017, 2017, 50910

(3) PIN, L. G.; Nadorova, A. V.; Antipova, T. A.; Kruglov, S. V.; Koudrin, V. S.; Durnev, A. D. Selank, Peptide Analogue de Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex

(4) PIN, L. G.; Nadorova, A. V.; Seredenin, S. B. Selank anpeche iperlokomosyon pwovoke etanòl ak manifestasyon sansibilizasyon konpòtman nan sourit DBA/2.. Bull Exp Biol Med 2016, 162 (1), 56-59. DOI: 10.1007/s10517-016-3544-6 Soti nan NLM Medline.

(5) Pri, N. V.; Sokolov, O.; Gabaeva, M. V.; Grivennikov, mwen. A.; Andreeva, L. A.; Miasoedov, N. F.; Zozulia, A. A. [Semax ak selank anpeche enkephalin-degrade anzim nan serom imen]]. Bioorg Khim 2001, 27 (3), 180-183. DOI: 10.1023/a:10113730028

(6) Mwen pa konnen, G. G.; Teleshova, E. S.; Bochkarev, V. K.; Koschelev, V. V.; Syunyakov, T. S. P.3.036 Novel anksyolitik Selank: Rezilta esè klinik Faz II yo. Ewopeyen neropsikofarmakoloji 2005, 15, S159-S160. DOI: 10.1016/s0924-977x(05)80332-3.

(7) Slominsky, P. A.; Shadrina, M. mwen.; Kolomin, T. A.; Stavrovskaya, A. V.; Filatova, E. V.; Andreeva, L. A.; Illarioshkin, S. N.; Myasoedov, N. F. Peptides semax ak selank afekte konpòtman rat ak 6-OHDA pwovoke PD ki sanble ak parkinsonism.. Dokl Biol Sc

(8) Sollertinskaja, T. N.; Chorokhov, M. V.; Myasoedov, N. F. Efè serebroprotective Semax ak Selank nan primat nan diferan kalite nevroz. Jounal Entènasyonal Sikofizyoloji 2008, 69 (3). DOI: 10.1016/j.ijpsycho.2008.05.356.

Sekans:

ac-thr-lys-pro-arg-pro-gly-pro-Adamantane-nh2

CAS:

N/A

M.W:

970.19 g/mol

Lakay Rechèch Whatsapp Sèvis Pwodwi